Skip to main content
Caplight Logo









Dialybrid S.r.l.

Dialybrid S.r.l.

Private
CantùHealthcare & Life Scienceshttps://dialybrid.com

Last Round

Series A

Sep 22, 2026

Total Funding Raised

$17.55M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Dialybrid S.r.l. operates in Healthcare & Life Sciences and is based in Cantù. Its latest recorded funding round was a Series A round in September 2026.

Dialybrid S.r.l. is a medical device company that develops and commercializes novel arteriovenous vascular grafts for hemodialysis using its proprietary Silkothane® technology.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Advanced Materials, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Dialybrid S.r.l. Comparables

Compare Dialybrid S.r.l. with similar companies based on industry and business-model similarity.

Dialybrid S.r.l. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Anova Biomedical
86%
Lingbo Biotechnology (Hangzhou) Co., Ltd.
84%
Xeltis
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Dialybrid S.r.l. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 22, 2026
SeedAug 4, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Dialybrid S.r.l. Investors

Notable investors and investment history

Dialybrid S.r.l. investors
InvestorRounds
XGEN VentureSeries A
CDP Venture Capital SGRSeries A
LIFTT EuroInvestSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 22, 2026

    $17M round led by XGEN Venture.

  • Aug 4, 2020

    $350K round led by LIFTT EuroInvest

Book a demo to see all signals

For institutional investors. Book with your work email.

Recent news

Latest coverage and updates

  • is_developingSep 22, 2026

    Dialybrid is developing a novel vascular access solution for hemodialysis based on Silkothane, with its first-in-human trial enrolling in Italy and the first patient successfully implanted on Sep 22nd '26.

  • receives_financingSep 22, 2026

    Dialybrid receives $17.2M Series A financing in Italy on Sep 22nd '26, in a round led by XGEN Venture with participation from CDP Venture Capital’s Rilancio Fund to fund clinical validation of its Silkothane(R) arteriovenous graft and preclinical development of the Silkothane(R) material for other vascular applications.

  • attends_eventSep 22, 2026

    Dialybrid will be attending LSI Europe '26 Emerging MedTech Summit in Spain on Sep 29th '26 and Sep 30th '26, where its CTO will present the company and participate in a panel discussion.

Book a demo to see all news

For institutional investors. Book with your work email.

Dialybrid S.r.l. Filings

Explore SEC and related filing metadata, where available.

Dialybrid S.r.l. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Dialybrid S.r.l.'s valuation, stock price, and market status.

Is Dialybrid S.r.l. a public or private company?

Dialybrid S.r.l. is a private company.

What is the current stock price of Dialybrid S.r.l.?

Dialybrid S.r.l. is a private company, so its shares have no public market price. Caplight tracks Dialybrid S.r.l.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Dialybrid S.r.l. worth (valuation)?

Valuation information for Dialybrid S.r.l. is not publicly available.

Can I buy Dialybrid S.r.l. stock?

Dialybrid S.r.l. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Dialybrid S.r.l.'s last funding round?

Dialybrid S.r.l.'s most recent funding round was Series A on September 22, 2026.

Who are the main investors in Dialybrid S.r.l.?

Key investors in Dialybrid S.r.l. include XGEN Venture, LIFTT EuroInvest.

Will Dialybrid S.r.l. IPO soon?

No public IPO plans have been announced for Dialybrid S.r.l..

How can I track Dialybrid S.r.l. secondary market activity?

Caplight tracks bids, offers, and trades in Dialybrid S.r.l.'s shares on secondary markets.

Firmographic Details

HeadquartersCantù
Employee Range5
Year Founded2020
Last FundingSep 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?